Hypertension
Feature
ACE inhibitors and severe COVID-19: Protective in older patients?
A randomized trial is planned after a study showed that fewer older hypertensive patients taking ACE inhibitors were hospitalized with COVID-19....
From the Journals
New angiotensin studies in COVID-19 give more reassurance
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
From the Journals
Angiotensin drugs and COVID-19: More reassuring data
From the Journals
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
From the Journals
Evidence suggests possible RAS-blocker benefit in COVID-19 patients
...
Feature
COVID-19 cases highlight longstanding racial disparities in health care
Data on higher infection and death rates in African Americans from COVID-19 may serve as a call to action.
News from the FDA/CDC
Hypertension goes unmedicated in 40% of adults
Conference Coverage
BPA analogs increase blood pressure in animal study
Female offspring of rats exposed to bisphenol-A, -S, and -F had higher daytime and nighttime blood pressure.
Conference Coverage
Renal denervation shown safe and effective in pivotal trial
First results of SPYRAL HTN-OFF MED indicate renal denervation may help fill the major unmet need for new treatments for hypertension.
Conference Coverage
Primordial cardiovascular prevention draws closer
“LDL and blood pressure, which are modifiable, may be more powerful determinants of lifetime risk than polygenic predisposition.” – Dr. Brian A....
Conference Coverage
Dramatic rise in hypertension-related deaths in the United States
The ‘alarming’ increase in hypertension-related deaths between 2007 and 2017, was particularly prominent in the rural South.